Lagunita BioSciences

Lagunita BioSciences is a venture capital firm and incubator based in Menlo Park, California, established in 2015. The company focuses on creating and nurturing early-stage enterprises that aim to commercialize innovative translational science to meet critical clinical needs. Its investment strategy encompasses sectors such as ophthalmology, drug discovery, oncology, medical devices, and digital health, positioning Lagunita BioSciences as a pivotal player in advancing healthcare solutions.

Christine Banian

Director

Thomas Krummel

Venture Partner

David Myung

Venture Partner

Daniel Palanker Ph.D

Venture Partner

6 past transactions

Kedalion Therapeutics

Series B in 2021
Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, founded in 2015. The company specializes in the development and commercialization of innovative topical ophthalmic therapies for various indications. Kedalion's proprietary AcuStream platform technology enhances the delivery of topical drugs to the eye with precision, allowing for comparable therapeutic effects while reducing the required dosage by up to 80% compared to traditional eye drops. This novel, digitally connected, electromechanical delivery device addresses the need for a user-friendly option that ensures reliable and comfortable administration of ocular therapies. By improving efficiency, patient comfort, and minimizing side effects, Kedalion aims to enhance the overall experience for both patients and healthcare providers while alleviating some of the burdens on the healthcare system.

Kedalion Therapeutics

Series A in 2018
Kedalion Therapeutics Inc. is an ophthalmic drug company based in Menlo Park, California, founded in 2015. The company specializes in the development and commercialization of innovative topical ophthalmic therapies for various indications. Kedalion's proprietary AcuStream platform technology enhances the delivery of topical drugs to the eye with precision, allowing for comparable therapeutic effects while reducing the required dosage by up to 80% compared to traditional eye drops. This novel, digitally connected, electromechanical delivery device addresses the need for a user-friendly option that ensures reliable and comfortable administration of ocular therapies. By improving efficiency, patient comfort, and minimizing side effects, Kedalion aims to enhance the overall experience for both patients and healthcare providers while alleviating some of the burdens on the healthcare system.

Verana Health

Series C in 2018
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

ViewPoint Therapeutics

Series B in 2018
ViewPoint Therapeutics, founded in 2014 and headquartered in San Francisco, specializes in developing treatments for diseases caused by protein misfolding. Its primary focus is on age-related cataracts, a leading cause of blindness worldwide. The company's innovative approach involves creating crystallin stabilizers, including a small molecule active in preclinical models of cataracts. These stabilizers aim to prevent or reverse protein misfolding, which underlies various common disorders associated with aging. ViewPoint Therapeutics is committed to advancing its pipeline to deliver effective therapies for these conditions.

ViewPoint Therapeutics

Series A in 2016
ViewPoint Therapeutics, founded in 2014 and headquartered in San Francisco, specializes in developing treatments for diseases caused by protein misfolding. Its primary focus is on age-related cataracts, a leading cause of blindness worldwide. The company's innovative approach involves creating crystallin stabilizers, including a small molecule active in preclinical models of cataracts. These stabilizers aim to prevent or reverse protein misfolding, which underlies various common disorders associated with aging. ViewPoint Therapeutics is committed to advancing its pipeline to deliver effective therapies for these conditions.

Verana Health

Series B in 2015
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.